CRANBURY, N.J., Nov. 11, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that data from a Phase I clinical study of CPI-613 for the treatment of advanced hematological malignancies will be presented by the principal investigator, Timothy S. Pardee, MD, of the Comprehensive Center of Wake Forest Baptist Medical Center, at the 2013 American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 7th-10th, 2013, in New Orleans, LA.
Help employers find you! Check out all the jobs and post your resume.
